Kohwa Biotechnology (002022.SZ) released its financial performance for the first half of the year, with a net loss attributable to shareholders of 133 million yuan.

Zhimedia Finance APP news, Ke Hua Biology (002022.SZ) released its 2025 interim report. During the reporting period, the company achieved operating income of 794 million yuan, a year-on-year decrease of 12.65%. The net loss attributable to shareholders of the listed company was 133 million yuan, and the net loss attributable to shareholders of the listed company after deducting non-recurring gains and losses was 140 million yuan, with a basic loss per share of 0.2595 yuan.